Clinical Laserthermia Systems: Q1’20 In Line With Expectations – Interesting Months Ahead
Redeye gives its view on CLS’s Q1’20 report. The report did not include any major surprises and the main interest among investors in the coming months will likely be on further news regarding the Thermoguide Software, additional orders as well as information about the upcoming proof-of-concept study in imILT®.